KINTOR PHARMA-B (09939): KT-939 Receives Notice of Grant of Invention Patent Right

KINTOR PHARMA-B (09939) announces that on October 21, 2026, the Group received a Notice of Grant of Invention Patent Right issued by the China National Intellectual Property Administration for KT-939 (Chinese trade name: OXIMIDOLKT-939, English trade name: OXIMIDOLKT-939), a novel high-efficiency tyrosinase inhibitor independently developed by the Group that inhibits melanin production. The patent relates to a tyrosinase inhibitor and its use (application number: 202580002670.3). A request for prioritized examination was submitted by Suzhou Kintor Pharmaceuticals, Ltd., a wholly-owned subsidiary of the Company, on March 27, 2026, and was granted prioritized examination by the China National Intellectual Property Administration on June 12, 2026. From the submission of the prioritized examination request to the issuance of the Notice of Grant of Invention Patent Right, the process took approximately 6 months. The Company is currently handling subsequent authorization and registration procedures in accordance with applicable laws. According to the text of the claims to be granted, the specific chemical structure of KT-939 (Chinese trade name: OXIMIDOLKT-939, English trade name: OXIMIDOLKT-939) is covered both by the specific compound claims of the patent application and falls within the scope of protection of its generic compound claims, and is therefore subject to the protection sought by the patent application. KT-939 is a core commercialized product of the Company. The grant of the invention patent for KT-939 in China is expected to help strengthen the competitive advantage of KT-939 in the high-end cosmetic ingredient market for whitening and spot removal. On September 18, 2026, the Company submitted all registration application materials for KT-939 as an efficacy cosmetic ingredient to the National Medical Products Administration (NMPA) and will strive to obtain NMPA approval as soon as possible. In addition, the Company is developing analogs of KT-939 as topical innovative drugs for the treatment of pigmentation-related disorders such as melasma.